Twist Bioscience Corporation (TWST) Tops Q4 EPS by 36c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results
November 18, 2022 7:30 AM EST-- Record revenue of $203.6 million in Fiscal 2022; Increase of 54% over $132.3 million in Fiscal 2021
-- Orders increased to $226 million in Fiscal 2022; Increase of 42% over $160 million in Fiscal 2021 --
Expect revenue in the range of $261 million to $269 million for full year Fiscal 2023 --
Expect revenue of $350 million for full year Fiscal 2024 --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
... More